Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea

CONCLUSIONS: This real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline.PMID:38619720 | DOI:10.1007/s12325-024-02832-x

Source: Adv Data - April 15, 2024 Category: Epidemiology Authors: Brian E Lacy Patrick Gagnon-Sanschagrin Zeev Heimanson Rebecca Bungay Remi Bellefleur Annie Gu érin Brock Bumpass Danellys Borroto George Joseph Ankur A Dashputre Source Type: research